Revvity The Alphalisa®Human Kras G12c/Sos1 Binding

KRAS, a small GTPase from the Rat sarcoma (RAS) oncogene family, is implicated in various biological processes, such as cell proliferation, cell survival, and cell metabolism. KRAS is mutated in many cancer subtypes and induces uncontrolled proliferation and cell metabolism modifications. KRAS thereby contributes to the Warburg effect in cancer cells. Like the majority of small GTPases, KRAS binds to GDP in its inactive form or binds to GTP to switch into active form. KRAS G12C is one of the most commonly present mutant forms in cancer which leads to a permanently active state of KRAS. The Ras guanine nucleotide exchange factor, also called SOS1, is a GEF protein promoting the active form of KRAS. The KRAS G12C SOS1 assay is a biochemical kit is designed to help identify novel inhibitors of KRAS G12C /SOS1 binding.

Formats

Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 20 µL reaction volume (5 µL of sample).Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 20 µL reaction volume (5 µL of sample).

Feature:

No-wash steps, no separation stepsELISA alternative technologySensitive detectionSmall sample volume

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.